Sucralfate or placebo following argon plasma coagulation for chronic radiation proctitis: a randomized double blind trial. (20th December 2012)

• Record Type: Journal Article
• Authors: Chruscielewska‐Kiliszek, M. R.; Regula, J.; Polkowski, M.; Rupinski, M.; Kraszewska, E.; Pachlewski, J.; Czaczkowska‐Kurek, E.; Butruk, E.
• Is Part Of: Colorectal disease. Volume 15:Number 1(2013)
• Page Start: e48
• Page End: e55
• Publication Date: 2012-12-20
• Subjects: Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.12035
• Languages: English
• ISSNs: 1462-8910

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p> <bold>Aim </bold> Chronic radiation proctitis is a long‐term complication of radiation therapy for pelvic malignancy. The aim of this study was to compare the efficacy and safety of two treatment regimens, sucralfate or placebo, following argon plasma coagulation (APC) for chronic haemorrhagic radiation proctitis.</p> <p> <bold>Method </bold> A single‐centre, randomized, placebo‐controlled, double‐blind study was performed on patients with haemorrhagic chronic radiation proctitis after irradiation for prostate, uterine, cervical, rectal or vaginal cancer. All patients received APC, and were then randomized to oral sucralfate (6 g twice a day) or placebo treatment for 4 weeks. APC was repeated every 8 weeks if necessary after the first session. Patients were graded clinically and endoscopically according to the Chutkan and Gilinski scales before and at 8 and 16 weeks after initial APC treatment (1.5–2 l/min, 25–40 W) and after 52 weeks (clinical only).</p> <p> <bold>Results </bold> Of 122 patients, 117 completed the entire protocol, with 57/60 in the sucralfate group and 60/62 in the placebo group. At baseline there were no significant differences between the sucralfate and placebo groups. At 1 year, a significant improvement in the clinical scale in both groups occurred compared with baseline. After 16 weeks, the median overall clinical severity scores fell from 4 to 2 points and the median bleeding score from 2 to 0 in both groups.</p> <p> <bold>Conclusion </bold> APC is safe and effective for the management of chronic radiation proctitis. Additional sucralfate treatment did not influence the clinical or endoscopic outcome.</p> </abstract>